Skip to content

Medical emergency? What to do

Drug firms eye fat profits from new obesity pills

3-RXPublished January 17, 20064 min read

Key points

  • A marijuana joint might seem an odd starting point in the search for weight-loss secrets.
  • Sanofi-Aventis SA's Acomplia, or rimonabant, which could be approved by U.S. regulators as early as next month, is the first of a new wave of treatments that may spell fat profits for some pharmaceutical companies.
  • Slimming pills have had a chequered history, due to modest effectiveness and adverse side effects -- most notoriously with the diet drug combination "fen-phen", which was linked to heart-valve problems and has cost Wyeth more than $21 billion in provisions related to patient claims.
  • Jonathan de Pass, chief executive of specialist consultancy Evaluate, calculates there are now 26 new drugs in clinical trials for obesity and a further 32 in early-stage development.

A marijuana joint might seem an odd starting point in the search for weight-loss secrets.

Yet a compound switching off the same brain circuits that make people hungry when they smoke cannabis looks set to become the world's first blockbuster anti-obesity medicine, with sales tipped by analysts to top $3 billion a year.

Sanofi-Aventis SA's Acomplia, or rimonabant, which could be approved by U.S. regulators as early as next month, is the first of a new wave of treatments that may spell fat profits for some pharmaceutical companies.

Another two experimental drugs from Arena Pharmaceuticals Inc and Alizyme Plc, with different mechanisms of action, have also produced promising clinical results in recent weeks, prompting some investors to start laying big bets on weight-loss medicine.

It is a risky area, however.

Slimming pills have had a chequered history, due to modest effectiveness and adverse side effects -- most notoriously with the diet drug combination "fen-phen", which was linked to heart-valve problems and has cost Wyeth more than $21 billion in provisions related to patient claims.

But past upsets have not deterred drug manufacturers from investing heavily in a new generation of possible winners.

MORE DRUGS IN PIPELINE

Jonathan de Pass, chief executive of specialist consultancy Evaluate, calculates there are now 26 new drugs in clinical trials for obesity and a further 32 in early-stage development.

In addition, at least half a dozen diabetes medicines are being tried out as treatments for reducing weight.

The potential market is large in every respect.

The World Health Organization (WHO) estimates more than 1 billion people in the world are overweight and, if current trends continue, that number will reach 1.5 billion by 2015.

Of the current total, more than 300 million already rank as obese, putting them at substantial risk of heart disease, stroke, type 2 diabetes, respiratory problems and some cancers.

Worryingly, the problem is also starting to spread rapidly in developing countries, including parts of Africa, and the western Pacific islands of Nauru and Tonga hold the dubious distinction of having the highest percentage rates of obesity in the world.

Given the scale of the problem, the arrival of new weight-loss drugs will be greeted with some excitement -- but they may also pose a dilemma.

Dr Timothy Armstrong of the WHO's department of chronic diseases believes medication can help only a very small minority of patients and will not impact the overall obesity epidemic.

"It's not a panacea," he said. "Drugs don't have a role in preventing obesity in the wider population, where interventions around physical activity and diet are far more cost-effective."

Professor Luc Van Gaal of Belgium's University Hospital Antwerp, the lead investigator for one of the main clinical studies for Acomplia, sees things rather differently.

He argues doctors must accept that dieting and exercise alone often produce disappointing results, leaving patients at risk of falling seriously ill.

"Drug therapy is not the answer for every obese person in the street, but for certain patients who are running a risk, pharmacological therapy can help," he said.

SIDE EFFECTS

Today, there are two main obesity medicines on the market -- Roche Holding AG's Xenical, which works by limiting fat absorption, and Abbott Laboratories Inc's Meridia/Reductil, which suppresses appetite.

Both can have adverse side effects, however. Xenical can cause excess gas and oily discharge, while Meridia may increase blood pressure. As a result, sales of both drugs are modest, at $460 million and $300 million respectively in 2004.

GlaxoSmithKline Plc hopes to win backing from a U.S. panel later this month for its own low-dose, low-side effect version of Xenical that would be sold without prescription -- although many industry experts still doubt it will become a major seller.

By contrast, the consensus forecast from analysts for peak sales of Acomplia is $3.1 billion, according to Evaluate, with some predictions topping $5 billion.

Just how big the drug will be, however, depends on the terms of use that Sanofi agrees with healthcare regulators.

The company hopes to prove that Acomplia specifically reduces key cardiovascular risk factors, since a simple obesity label may not be enough secure widespread reimbursement from governments and insurers.

Side effects could also be an issue. While patients on Acomplia have lost around 7 kg (15 lb) in body weight over two years, concerns remain about its potential impact on mood.

Still, rivals clearly think Sanofi is onto something big, with Merck & Co Inc, Pfizer Inc and Bristol-Myers Squibb Co among a clutch of companies now developing similar cannabinoid receptor blocking drugs.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.